| Methods |
Single‐centre |
| Participants |
n = 16 vs 16
Average age = 45.7 (range 30‐65) in the FOLFOX4 group, and 42.1 (range 26‐70) in the SOX group. |
| Interventions |
"Total of 32 patients with advanced gastric cancer proved pathologically were randomly divided into 2 groups: 16 patients received SOX regimen [oxaliplatin 1.30 mg/m2 as a 2‐hour infusion on day 1, S‐1 capsules 80 mg/m2·d) twice a day per oral from day 1 to day 14 every 3 weeks], the other 16 patients received FOLFOX4 regimen [oxaliplatin 85 mg/m2 as a 2 hour infusion on day 1 and a 2 hour infusion of LV 200/(m2·d) followed by a 5‐Fu bolus 400/(m2·d) and 22 hour infusion 600/(m 2·d) for 2 consecutive days every 2 weeks]. Efficacy was evaluated at least 2 cycles" |
| Outcomes |
Response rates
Disease control rates
PFS
OS
Safety |
| Notes |
PFS and OS were not analysed using Kaplan‐Meier methods. HR for PFS could be estimated from summary data but HR for OS could not. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Simple random assignment |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
efficacy |
High risk |
Time‐to‐event analysed not analysed using Kaplan‐Meier methods. |
| Incomplete outcome data (attrition bias)
safety |
High risk |
Quantitative comparison only made for grade 3 or higher haematological toxicity |
| Selective reporting (reporting bias) |
Unclear risk |
N/A |
| Other bias |
Unclear risk |
N/A |
| Blinded review of CT/MRI‐scans? |
Unclear risk |
Not stated |
